Search

everythinglearnresearchcommunity

for

Search:↓

Patients with autoimmune blistering diseases experience a reduced quality of life, with the need for better measurement tools, especially for those with mucous membrane pemphigoid.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

New treatments for alopecia areata show promise but need ongoing use and have infection risks.

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Modified superoxide dismutase may trigger an autoimmune response in alopecia areata.

A new test using NOS2 and CCL27 genes can better diagnose and treat psoriasis and eczema.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

Alopecia areata is linked to autoimmune antibodies.

The patient with autoimmune hypothyroidism improved after treatment for thyroid and associated conditions.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

Arab APS1 patients have unique and recurrent AIRE gene mutations.

Belimumab may cause hair loss in lupus patients.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Premature aging increases the risk of immune problems and autoimmune diseases.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

Rituximab improved her dermatomyositis better than usual treatments.

Skin problems are common and early signs of Systemic Lupus Erythematosus, and certain immune system markers are important for diagnosis and treatment.

Bacterial vaginosis is not linked to skin disorders in these patients.

A woman with lupus had unusual symptoms like blisters, skin inflammation, and throat ulcers, which improved with steroid and dapsone treatment.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

The S250C variant in a gene may cause autoimmunity and immunodeficiency by impairing protein function.

Trichoscopy helps quickly identify autoimmune diseases on the scalp but should be used with other standard tests.

People with Down syndrome have higher rates of certain immune-related conditions and need special medical attention.

Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.